TNFRSF11B gene polymorphisms increased risk of peripheral arterial occlusive disease and critical limb ischemia in patients with type 2 diabetes

Biscetti, Federico; Porreca, Carlo Filippo; Bertucci, F.; Straface, Giuseppe; Santoliquido, Angelo; Tondi, Paolo; Angelini, Flavia; Pitocco, Dario; Santoro, Luca; Gasbarrini, Antonio; Landolfi, Raffaele; Flex, Andrea

doi:10.1007/s00592-014-0664-1

Cited by 35 publications

(26 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…37, 38 The use of a more appropriate instrumental technique that is more accurate, especially in identifying early lesions, could also facilitate the association of PAD with novel biomarkers of the atherosclerosis process associated with pathways of inflammation, lipoprotein and adipocyte metabolism, hemodynamic stress, calcification and hemostasis. 39, 40 …”

Section: Discussionmentioning

confidence: 99%

New semiquantitative ultrasonographic score for peripheral arterial disease assessment and its association with cardiovascular risk factors

Santoro

Ferraro²,

Flex

et al. 2016

Hypertens Res

Self Cite

View full text Add to dashboard Cite

The data concerning the distribution, extent and progression of peripheral arterial disease (PAD), as well as its association with traditional cardiovascular (CV) risk factors, have generally been obtained from studies of patients in advanced stages of the disease undergoing surgical or endovascular treatment. In this study, we have introduced a new semiquantitative ultrasonographic score (ultrasonographic lower limb atherosclerosis (ULLA) score) that is able to categorize lower limb atherosclerotic lesions at all stages of PAD. We then associated these ultrasonographic categories with a CV risk profile. We enrolled 320 consecutive subjects with symptoms suggestive of PAD or with known CV risk factors referring to our angiology unit between 1 July 2014 and 30 June 2015 for ultrasonographic evaluation of the lower limb arteries. Femoropopliteal and run-off segments were categorized together and separately based on their ultrasonographic characteristics. In univariate and multivariate analyses, the ULLA scores were significantly associated with the main CV risk factors, that is, age, male gender, cigarette smoking, arterial hypertension, diabetes, dyslipidemia, sedentary lifestyle, previous CV events and family history of CV disease, and also confirming the specific association of single risk factors with different segments of lower limb arteries. The proposed ULLA score enables a complete evaluation of the entire lower limb atherosclerotic burden, extending the results concerning the association of PAD with CV risk factors to all stages of the disease, including the early stages. It can be feasible that this new score will facilitate better evaluation of the progression of PAD and its prospective role in CV risk stratification.

show abstract

Section: Discussionmentioning

confidence: 99%

New semiquantitative ultrasonographic score for peripheral arterial disease assessment and its association with cardiovascular risk factors

Santoro

Ferraro²,

Flex

et al. 2016

Hypertens Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…Even the abnormal release of nitric oxide (NO), which characterized the diabetic environment, directly promotes endothelial dysfunction [56]. In addition, hyperglycemia promotes calcification in atherosclerotic plaque and in the tunica media of large and medium size arteries, through a major mobilization of osteoprogenitor cells, from bone marrow to the vascular wall [41,54,[57][58][59]. Moreover, hyperglycemia can promote vascular injury with an indirect action of other risk factors, such as low-density lipoprotein (LDL) cholesterol [54].…”

Section: Diabetic Macroangiopathymentioning

confidence: 99%

High Mobility Group Box-1 and Diabetes Mellitus Complications: State of the Art and Future Perspectives

Biscetti

Rando

Nardella

et al. 2019

IJMS

View full text Add to dashboard Cite

Diabetes mellitus (DM) is an endemic disease, with growing health and social costs. The complications of diabetes can affect potentially all parts of the human body, from the heart to the kidneys, peripheral and central nervous system, and the vascular bed. Although many mechanisms have been studied, not all players responsible for these complications have been defined yet. High Mobility Group Box-1 (HMGB1) is a non-histone nuclear protein that has been implicated in many pathological processes, from sepsis to ischemia. The purpose of this review is to take stock of all the most recent data available on the role of HMGB1 in the complications of DM.

show abstract

“…Despite multiple therapeutic approaches and multidisciplinary management, de nite biomarkers, useful to stratify the risk for T2DM patients with PAD and CLTI are not available [26,27]. Regarding follow-up after revascularization, even less clear evidence is available [28]. In fact, outcomes after LER vary widely among T2DM patients [6].…”

Section: Discussionmentioning

confidence: 99%

Association between omentin-1 and major cardiovascular events after lower extremity endovascular revascularization in diabetic patients: a prospective cohort study

Biscetti

Nardella

Rando

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Cardiovascular complications represent the major cause of morbidity and mortality of type 2 diabetes mellitus (T2DM) patients. In particular, peripheral artery disease (PAD) represents a frequent T2DM vascular complication and a risk factor for the development of major adverse cardiovascular events (MACE). Among adipokines, omentin-1 serum levels are reduced in T2DM patients with PAD and are inversely related to disease severity.Objective: To study the relationship between omentin-1 levels, at baseline, with outcomes after endovascular procedures in T2DM patients with PAD and chronic limb-threatening ischemia (CLTI).Research Design and Methods: We enrolled for our prospective non-randomized study, 207 T2DM patients with PAD and CLTI, requiring revascularization. Omentin-1 serum levels were collected before revascularization and patients incidence outcomes were evaluated at 1, 3, 6 and 12 months.Results: Omentin-1 was reduced in patients with more severe disease (27.24 ± 4.83 ng/mL vs 30.82 ± 5.48 ng/mL, p < 0.001). Overall, 84 MACE and 96 major adverse limb events (MALE) occurred during the 12-month follow-up. We observed that omentin-1 levels were lower in patients with MACE (26.02 ± 4.05 ng/mL vs 31.33 ± 5.29 ng/mL, p < 0.001) and MALE (26.67 ± 4.21 ng/mL vs 31.34 ± 5.54 ng/mL, p < 0.001). The association between omentin-1, MACE and MALE remained significant after adjusting for major risk factors in a multivariate analysis. Receiver operating characteristics (ROC) curve using omentin-1 levels predicted incidence events (area under the curve = 0.80).Conclusions: We demonstrated that reduced omentin-1 levels, at baseline, are related with worse vascular outcomes in T2DM patients with PAD and CLTI undergoing an endovascular procedure.

show abstract

TNFRSF11B gene polymorphisms increased risk of peripheral arterial occlusive disease and critical limb ischemia in patients with type 2 diabetes

Abstract: The TNFRSF11B gene polymorphisms under study are associated with PAOD, and synergistic effects between these genotypes might be potential markers for the presence and severity of atherosclerotic disorders.

Cited by 35 publications

References 41 publications

New semiquantitative ultrasonographic score for peripheral arterial disease assessment and its association with cardiovascular risk factors

New semiquantitative ultrasonographic score for peripheral arterial disease assessment and its association with cardiovascular risk factors

High Mobility Group Box-1 and Diabetes Mellitus Complications: State of the Art and Future Perspectives

Association between omentin-1 and major cardiovascular events after lower extremity endovascular revascularization in diabetic patients: a prospective cohort study

Contact Info

Product

Resources

About